Table 4:
Hyperkalaemia treatment objective and initial management strategy by provider specialty.
| Characteristics | Nephrologists | Non-nephrologists | Cardiologists | Non-cardiologists |
|---|---|---|---|---|
| Participants with provider specialty reported, n | 597 | 327 | 237 | 687 |
| Treatment objective, n (%) | ||||
| Number with response | 553 | 313 | 227 | 639 |
| Ease of treatment | 196 (35) | 145 (46) | 77 (34) | 264 (41) |
| Safety | 170 (31) | 97 (31) | 92 (41) | 175 (27) |
| Heart failure guidelines | 18 (3) | 72 (23) | 66 (29) | 24 (4) |
| CKD guidelines | 285 (52) | 26 (8) | 14 (6) | 297 (47) |
| Adjust RAASi | 50 (9) | 36 (12) | 34 (15) | 52 (8) |
| Initial management strategy, n (%) | ||||
| Number with response | 588 | 327 | 237 | 678 |
| Low K+ diet | 400 (68)b | 71 (22) | 42 (18)b | 429 (63) |
| ACEi/ARB/ARNIa | 265 (45)b | 194 (59) | 42 (18)c | 429 (63) |
| Discontinued | 12 (5) | 8 (4) | 8 (6) | 12 (4) |
| Dose reduced | 8 (3) | 5 (3) | 5 (4) | 8 (2) |
| Dose maintained | 237 (88) | 170 (88) | 115 (83) | 292 (91) |
| Dose increased | 4 (2) | 6 (3) | 6 (4) | 4 (1) |
| Started | 7 (3) | 8 (4) | 7 (5) | 8 (2) |
| MRAa | 26 (4)b | 99 (30) | 90 (38)b | 35 (5) |
| Discontinued | 5 (19) | 17 (17) | 15 (17) | 7 (20) |
| Dose reduced | 2 (8) | 13 (13) | 12 (13) | 3 (9) |
| Dose maintained | 18 (69) | 65 (66) | 59 (66) | 24 (69) |
| Dose increased | 1 (4) | 1 (1) | 1 (1) | 1 (3) |
| Started | 0 | 5 (5) | 5 (6) | 0 |
| K+ bindera | 152 (26)b | 45 (14) | 39 (16)c | 158 (23) |
| Discontinued | 1 (0.7) | 0 | 0 | 1 (1) |
| Dose reduced | 1 (0.7) | 0 | 0 | 1 (1) |
| Dose maintained | 58 (38) | 10 (22) | 8 (21) | 60 (38) |
| Dose increased | 21 (14) | 2 (4) | 1 (3) | 22 (14) |
| Started | 71 (47) | 33 (73) | 30 (77) | 74 (47) |
| Dialysis (started, unscheduled, changed prescription) | 24 (4)b | 0 | 0b | 24 (4) |
Participants can be counted in more than one row. Not all response options are shown. P-value calculated by Fisher's exact test for dialysis comparisons or by Pearson's chi-squared test for other comparisons.
a
For medication dose change or discontinuation, n is the number of participants for whom a response is provided for the medication category. Denominator for calculating the percentage is the number of participants for whom any initial management strategy is provided.
b
P < .0001 versus non-nephrologists or non-cardiologists.
c
P < .05 versus non-cardiologists.